Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been given an average recommendation of “Hold” by the twenty-nine analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $491.49.

A number of equities analysts recently commented on REGN shares. Sanford C. Bernstein reiterated an “outperform” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, May 25th. Leerink Swann reiterated an “outperform” rating and set a $493.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, June 13th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 14th. Piper Jaffray Companies lifted their price target on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a report on Tuesday, June 20th. Finally, BMO Capital Markets reiterated a “market perform” rating and set a $421.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 21st.

COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Given Consensus Rating of “Hold” by Analysts” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/21/regeneron-pharmaceuticals-inc-regn-given-consensus-rating-of-hold-by-analysts.html.

In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 1,305 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $470.00, for a total transaction of $613,350.00. Following the completion of the transaction, the chairman now directly owns 329,543 shares in the company, valued at $154,885,210. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 85,968 shares of company stock valued at $40,699,948. Company insiders own 10.40% of the company’s stock.

Several large investors have recently made changes to their positions in REGN. BlackRock Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 3,331.5% during the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Regeneron Pharmaceuticals by 15,495.4% during the second quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock worth $767,637,000 after buying an additional 1,552,948 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Regeneron Pharmaceuticals by 74.1% during the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after buying an additional 550,247 shares in the last quarter. Janus Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 58.5% during the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after buying an additional 486,119 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Regeneron Pharmaceuticals by 7.9% during the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter last year, the company posted $2.82 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% on a year-over-year basis.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.